Biotech researchers across the world are experiencing a renaissance in their industry. Like the massive growth experienced by technology companies of the 90s, the biotech industry is prepped and ready to realize the same growth. Technology has provided new ways to research treatments, therapies and distribute new drugs. Many small biotech companies have taken advantage of this new technology and are the source of these new drugs. With many patents expiring in 2012, the large corporations are beginning to acquire these smaller companies in an effort to attain new patents.

With new discoveries every day in the biotech industry the shelf life of a new drug is becoming shorter. According to information gathered by Bloomberg, 676 biotech takeovers occurred in rising numbers over the last 3 years. Expect this trend to continue over the next 3 years, as more patents will expire and new drugs will be discovered at an increasingly higher rate.

Researchers have just started to scratch the surface in this young and exciting field. 2012 revealed many advances in the Anti-obesity, Myelofibrosis, cancer, HCV, RA, MS, psoriasis, HCC, and dyslipidemia fields. 2013 promises to discover new treatments for viruses, targeted cancer treatments, Alzheimer's, antivirals and orphan diseases. In addition, many oral therapies are being researched in the areas of RA, Psoriasis, and MS. Stem cell research will also be represented well in 2013.

Investors continue to be unafraid of the lengthy and difficult process to achieve FDA approval. In fact, many have plans to increase the M&A budgets. Many small biotech companies are also seeing the oncoming wave of advancements in this field and have decided to take on the challenge of doing their own marketing. The rewards well outweigh the risks for these small biotech companies.

The biotech industry has many up and coming companies that are worth taking a closer look.

International Stem Cell Corporation (OTCQB: ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). http://www.firstpennypicks.com/get-your-free-research-report/

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development of high performance polymers. Kraig works in cooperation with leading universities in the fields of genetics and genetic engineering to develop new recombinant fibers and materials which the company believes will have broad commercial applications. http://www.firstpennypicks.com/get-your-free-research-report/

ScripsAmerica, Inc. (OTCQB: SCRC) delivers pharmaceutical products to a wide range of end users across the health care industry, including physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies through the largest pharmaceutical distributor in North America, McKesson Corporation. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration. http://www.firstpennypicks.com/get-your-free-research-report/

Celsion Corp. (NASDAQ: CLSN) is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital and the Beijing Cancer Hospital. http://www.firstpennypicks.com/get-your-free-research-report/

http://www.Firstpennypicks.com was developed as a beacon of hope in the micro-cap stock newsletter industry. We always hand-pick our alerts as opposed to biased advertising. This is why we are the fastest growing community of micro-cap traders on the web.

Please note that all media from Elite Traders Group LLC and FirstPennyPicks.com is investment opinion only. Elite Traders Group employees are not registered as an Investment Adviser in any jurisdiction whatsoever. This advertisement is for informational purposes only and is not intended to be a recommendation to buy or sell securities in any of the profiled companies listed here.

Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements.
In his session at DevOps Summ...

One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences.
In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific...

The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and...

SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY.
Isomorphic Software is ...

SYS-CON Events announced today that AgilePoint, the leading provider of Microsoft-centric Business Process Management software, will exhibit at SYS-CON's 2nd International @ThingsExpo which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara...